-
Screening for pre-eclampsia using sFlt-1/PlGF ratio cut-off of 38 at 30-37 weeks' gestation.
Dragan I, Georgiou T, Prodan N, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:73-77. pdf -
Maternal cardiac function at 35-37 weeks' gestation: prediction of pre-eclampsia and gestational hypertension.
Guy GP, Ling HZ, Garcia P, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:61-66. pdf -
Maternal cardiovascular function at 35-37 weeks' gestation: Relation to maternal characteristics.
Guy GP, Ling HZ, Garcia P, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:39-45. pdf -
Development of preeclampsia within four weeks of sFLT to PLGF ratio >38: Comparison of performance at 31-34 versus 35-37 weeks' gestation.
Dragan I, Wright D, Fiolna M, Leipold G, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:209-12. pdf -
Can Staining of Damaged Proteins in Urine Effectively Predict Preeclampsia?
Sammar M, Syngelaki A, Sharabi-Nov A, Nicolaides K, Meiri H.
Fetal Diagn Ther 2017;41:23-31. pdf -
Metabolomic determination of pathogenesis of late-onset preeclampsia.
Bahado-Singh RO, Syngelaki A, Mandal R, Graham SF, Akolekar R, Han B, Bjondahl TC, Dong E, Bauer S, Alpay-Savasan Z, Turkoglu O, Ogunyemi D, Poon LC, Wishart DS, Nicolaides KH.
J Matern Fetal Neonatal Med 2017;30:658-64. pdf -
The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis.
Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E.
Am J Obstet Gynecol 2017;216:110-120.e6. pdf -
Comparison of screening for pre-eclampsia at 31-34 weeks' gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF.
Tan MY, Wright D, Koutoulas L, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:201-8. pdf -
Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 30-34 weeks' gestation.
Wright D, Dragan I, Syngelaki A, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:194-200. pdf -
Assessment of body composition in Wistar rat offspring by DXA in relation to prenatal and postnatal nutritional manipulation.
Eleftheriades M, Vafaei H, Dontas I, Vaggos G, Marinou K, Pervanidou P, Sebire NJ, Chrousos GP, Nicolaides KH.
Pediatr Res 2016;80:319-25. pdf -
Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE)
O'Gorman N, Wright D, Rolnik DL, Nicolaides KH, Poon LC.
BMJ Open 2016;6:e011801. pdf -
Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks' gestation.
Andrietti S, Silva M, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;48:72-9. pdf -
Maternal serum PAPP-A and free beta-hCG at 12, 22 and 32 weeks' gestation in screening for pre-eclampsia.
Wright A, Guerra L, Pellegrino M, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:762-7. pdf -
Maternal serum soluble fms-like tyrosine kinase-1 at 22 and 32 weeks in the prediction of pre-eclampsia.
Wright D, Krajewska K, Bogdanova A, Wright A, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:755-61. pdf -
Mean arterial pressure at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
Tayyar A, Krithinakis K, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:573-9. pdf -
Uterine artery pulsatility index at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
O'Gorman N, Tampakoudis G, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:565-72. pdf -
Contingent screening for preterm pre-eclampsia.
Wright D, Gallo DM, Gil Pugliese S, Casanova C, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:554-9. pdf -
Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysis.
Roberge S, Demers S, Nicolaides KH, Bureau M, Côté S, Bujold E.
Ultrasound Obstet Gynecol 2016;47:548-53. pdf -
Maternal serum soluble fms-like tyrosine kinase-1 at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
Tsiakkas A, Mendez O, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:478-83. pdf -
Maternal serum placental growth factor at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
Tsiakkas A, Cazacu R, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:472-7. pdf